Histotripsy

Histotripsy is an image-guided focused-ultrasound method that uses very short, high-amplitude ultrasound pulses to create controlled acoustic cavitation inside a targeted volume of soft tissue. The rapidly forming and collapsing microbubble cloud mechanically disrupts tissue at a subcellular level. In cancer care it is best understood as a local ablation technology, not as a systemic cancer therapy or a general cancer cure.

The leading commercial platform is the HistoSonics Edison System. The FDA De Novo summary for DEN220087 identifies the device as a focused ultrasound system for non-thermal, mechanical tissue ablation and indicates it for non-invasive destruction of liver tumors, including unresectable liver tumors. The same FDA summary and HistoSonics labeling language are important: the system has not been evaluated by FDA for treatment of a specific disease or condition, and FDA has not established cancer-specific outcomes such as local tumor progression, five-year survival, or overall survival.

How It Is Thought To Work

Unlike thermal high-intensity focused ultrasound, radiofrequency ablation, microwave ablation, cryoablation, or radiation therapy, histotripsy aims to destroy tissue mechanically rather than by heating, freezing, cutting, or ionizing radiation. Ultrasound imaging helps the operator localize the lesion and visualize the treatment effect while the system delivers a planned series of cavitation pulses through an external acoustic path.

Because the treatment is local, it only addresses the targeted tumor volume. It does not treat microscopic disease elsewhere in the body, circulating tumor cells, distant metastases outside the treated field, or the underlying biology that caused the cancer. For many patients it would be considered alongside surgery, ablation, embolization, radiation, systemic therapy, transplant planning, or observation depending on tumor type, stage, liver function, anatomy, prior treatment, and goals of care.

Current Cancer Use

The clearest current use is selected primary and metastatic liver tumors, including hepatocellular carcinoma and liver metastases from cancers such as colorectal, breast, pancreatic, uveal melanoma, and other primaries when the tumor is targetable in the liver. The HistoSonics trial portfolio describes the #HOPE4LIVER pivotal trial as enrolling 47 participants with 52 treated tumors and reporting technical success in 95.5% of evaluable lesions within 36 hours, a 6.8% procedure-related major complication rate, 90% one-year local tumor control by imaging core laboratory Kaplan-Meier estimate, and one-year overall survival of 73.3% for HCC and 48.6% for liver metastasis participants.

The earlier THERESA first-in-human feasibility trial enrolled 8 eligible patients with 11 treated liver tumors, including colorectal liver metastases, breast metastasis, cholangiocarcinoma metastases, and hepatocellular carcinoma. The trial reported that the primary technical endpoint was achieved in all procedures and no device-related adverse events were identified through the short follow-up window.

Investigational Areas

Kidney tumors are a major investigational direction. HistoSonics announced in May 2026 that it submitted a new FDA De Novo request seeking authorization to expand Edison use to kidney or renal tumors. That submission was supported by the #HOPE4KIDNEY trial, described as a prospective, multicenter, single-arm pivotal study that enrolled 67 patients with solitary non-metastatic solid renal tumors. As of this update, kidney use remains investigational.

Pancreatic cancer is also being studied. The HistoSonics trial portfolio lists the GANNON feasibility trial for unresectable pancreatic adenocarcinoma in locally advanced or oligometastatic disease after at least 8 weeks of chemotherapy. Prostate work listed by HistoSonics is directed at benign prostatic hyperplasia rather than prostate cancer, so prostate cancer should not be presented as an established histotripsy cancer indication.

Potential Advantages

Reported and proposed advantages include no incision, no inserted ablation needle, no ionizing radiation, nonthermal tissue destruction, real-time ultrasound visualization of the bubble cloud, a sharply planned treatment volume, and the possibility of treating some lesions that are difficult for surgery or thermal ablation. Because it is nonthermal, histotripsy may avoid some heat-sink limitations of thermal ablation near blood vessels, although patient selection remains highly anatomy-dependent.

Limitations And Risks

Histotripsy requires a target that can be visualized and reached through a safe acoustic pathway. Lesions may be unsuitable because of size, location, intervening bowel, ribs, lung, scar tissue, poor ultrasound visibility, proximity to vulnerable structures, inadequate liver function, excessive tumor burden, or patient-specific anesthesia/procedure risks. In pivotal liver work, many targets were small, selected, and followed in single-arm rather than randomized trials.

Reported complications and safety concerns include pain, skin or soft tissue injury along the acoustic path, thrombosis, infection/sepsis, portal vein thrombosis, hepatic failure, pleuritic pain, acute kidney injury, and rare death in high-risk patients with heavy liver tumor burden. Post-market reports are useful signals but cannot by themselves establish reliable event rates. The risk-benefit discussion should therefore be individualized and handled by trained clinicians familiar with the device and with liver tumor care.

How To Position It

For this database, Histotripsy is best categorized as an experimental/emerging technical local-treatment method. It is real medical-device technology with regulatory authorization for destruction of liver tumors, but its long-term survival effect, optimal sequencing, best cancer subgroups, and expansion beyond liver remain under active study. It should be described as a promising local treatment option for selected liver tumor cases and an investigational platform for kidney, pancreas, and other sites.

Source Notes

Key sources include the FDA De Novo summary for Edison System DEN220087, the HistoSonics clinical evidence and trial portfolio pages, the THERESA feasibility trial, the #HOPE4LIVER pivotal and one-year publications listed by HistoSonics, the HistoSonics CE Mark announcement of July 13, 2026, and the HistoSonics May 11, 2026 kidney De Novo submission announcement.